株式会社PRISM BioLab Logo

株式会社PRISM BioLab

A biotech creating novel drugs by targeting previously "undruggable" protein interactions.

206A | T

Overview

Corporate Details

ISIN(s):
JP3833190006
LEI:
Country:
Japan
Address:
藤沢市村岡東二丁目26番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PRISM BioLab is a biotechnology company dedicated to creating novel small molecule drugs for diseases that currently lack effective treatments. The company's core is its proprietary PepMetics® drug discovery platform, which enables the targeting of previously "undruggable" proteins. This technology utilizes unique small molecule scaffolds that mimic peptide structures (α-helices and β-turns) to control protein-protein interactions (PPIs), a key cause of many diseases. By making these challenging targets accessible, PRISM BioLab aims to pioneer new therapies and collaborates with pharmaceutical companies to advance its drug discovery programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-17 09:30
Major Shareholding Notification
臨時報告書
Japanese 21.0 KB
2025-05-14 09:31
Registration Form
確認書
Japanese 8.7 KB
2025-05-14 09:30
Interim Report
半期報告書-第14期(2024/10/01-2025/09/30)
Japanese 224.7 KB
2024-12-27 07:34
Governance Information
内部統制報告書-第13期(2023/10/01-2024/09/30)
Japanese 22.2 KB
2024-12-27 07:33
Registration Form
確認書
Japanese 8.7 KB
2024-12-27 07:32
Registration Form
有価証券報告書-第13期(2023/10/01-2024/09/30)
Japanese 3.1 MB
2024-12-27 07:31
Post-Annual General Meeting Information
臨時報告書
Japanese 22.1 KB
2024-11-14 07:32
Regulatory News Service
臨時報告書
Japanese 20.8 KB
2024-10-16 10:12
Major Shareholding Notification
臨時報告書
Japanese 20.7 KB
2024-09-10 09:09
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2024-06-24 08:00
Prospectus
訂正有価証券届出書(新規公開時)
Japanese 2.2 MB
2024-06-14 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.3 MB
2024-05-27 08:00
Registration Form
有価証券届出書(新規公開時)
Japanese 4.3 MB

Automate Your Workflow. Get a real-time feed of all 株式会社PRISM BioLab filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 株式会社PRISM BioLab

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 株式会社PRISM BioLab via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America
CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France
ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea
471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan
7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan
4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.